Zydus Lifesciences share price: Zydus Lifesciences shares rose 7% following USFDA's final approval to market Dasatinib tablets across multi...

LIC Housing Finance said its board has given a nod to borrow Rs 1.23 lakh crore through loans, issue of bonds, and other instruments, in th...

Indian oil explorer Oil and Natural Gas Corp said its unit acquired clean energy firm PTC Energy for Rs 925 crore ($106.02 million) as the ...

Biocon has tentative approval from USFDA for Dasatinib Tablets, which are used to treat Philadelphia Chromosome Positive Chronic Myeloid Le...

Lupin in partnership with Pharmascience Inc. has received approval from the US Food and Drug Administration (FDA) for Dasatinib tablets in ...

Dasatinib Tablet is indicated for the treatment of newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) i...

The drug substance patent on Dasatinib was owned by Bristol-Myers-Squibb and had expired on 12 April 12, 2020. The current monthly therapy ...

The ministry has received a proposal from the Ministry of Health and Family Welfare for grant of CL in respect of the drug.

Lee Pharma filed the application on June 29 to make a generic version of the patented drug, marketed as Onglyza, under Section 84 of the Pa...

The ministry has sought details from the Health Ministry, which had approached the DIPP for issuance of compulsory licences.

DIPP has shot down a health ministry proposal to consider a government-initiated compulsory licence for cancer drug Dasatinib.

Under the Indian Patents Act, if a medicine is deemed unaffordable, a compulsory licence can be issued to a generic drug maker in public in...

CL can be invoked by a national government allowing a company to produce a patented product without the consent of the patent owner in publ...

The Mumbai-based firm has applied to the Controller of Patents, Mumbai, seeking the CL for "ease of availability" and "affordability" of th...

BDR Pharma has filed an application with the Mumbai Patent Office, seeking compulsory licence to market a crucial cancer drug, dasatinib

The IPAB has upheld the compulsory licence issued to Natco Pharma for production and marketing of generic version of cancer drug Nexavar.

DIPP has sought details from the Health Ministry regarding three medicines sold by multinationals in India to make them affordable.